I appreciate your insight Melon. It is much appreciated. But I will have to respectfully disagree at least in part with your statement saying "A small company like this cannot be expected to meet the complex deadlines of clinical studies in many countries and the decisions relating to them."
Yes this has been an eye opener for me with regards to how drawn out this process can be. But they have been doing this for many years now and you think they would understand this by now. Why continue to put out dates that really have not been attainable ever? Try putting a date farther out, then come through early.
I could attribute it to a lack of management experience in this field. In Pluristem's company info, three of them came from Elbit Systems, including the twins. Very few have any sort of pharma experience, even with the souped up experience section. Why not bring in some sort of pharma executive with real experience in this field. Lure them with a ton of options. Better than the gifting to the twins, amd the promotion to make them twins. And what about this secretive top notch CRO they hired. Wouldn't they be a little more knowledgeable about timeframes. I guess they could have been the ones to mislead them on that one.
And what about stuff that doesn't deal with the clinical process. Japan gave the green light on the fast track almost 2 years ago. Where is the partnership? Postponed twice now and waiting for it to close still.
And what about partnerships in general. Are they going it alone now? They made it sound like partnerships would be coming for years now but crickets are what we get.
If they would actually just talk to shareholders on a regular basis and explain what is going on aside from a 5 or 10 page at most, year end update we get. It is horrible how they communicate with the public.
So for these reasons I am not a fan of management at all, and will continue to be until things change.
